Search research articles
Contact Us
Filters
Showing results (1141-1150 of 1,873) with videos related to
Page
of 188
Sort By:
European Journal of Heart Failure
|
February 10, 2021
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis
Luis E Rohde, Muthiah Vaduganathan, Brian L Claggett, et al.
European Heart Journal
|
February 4, 2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
Michael Böhm, Robin Young, Pardeep S Jhund, et al.
American Journal of Nephrology
|
December 15, 2017
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial
Finnian R Mc Causland, Brian Claggett, Marc A Pfeffer, et al.
American Journal of Ophthalmology
|
March 3, 2018
Shortest Distance From Fovea to Subfoveal Hemorrhage Border Is Important in Patients With Neovascular Age-related Macular Degeneration
Saleema Kherani, Adrienne W Scott, Adam S Wenick, et al.
Journal of Hepatology
|
June 25, 2017
Human germline hedgehog pathway mutations predispose to fatty liver
Maria J Guillen-Sacoto, Ariel F Martinez, Yu Abe, et al.
Circulation
|
April 30, 2019
High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study
Xiaoming Jia, Wensheng Sun, Ron C Hoogeveen, et al.
European Journal of Heart Failure
|
September 19, 2018
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction
Adriaan A Voors, Sanjiv J Shah, Jeroen J Bax, et al.
Journal of Cardiac Failure
|
May 23, 2023
Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
John W Ostrominski, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure
|
March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Alberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
Nature Medicine
|
March 30, 2026
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial
Scott D Solomon, John J V McMurray, G Michael Felker, et al.
Page
of 188
Search research articles
Search
Showing results (1141-1150 of 1,873) with videos related to
Sort By:
Page
of 188
European Journal of Heart Failure
|
February 10, 2021
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis
Luis E Rohde, Muthiah Vaduganathan, Brian L Claggett, et al.
European Heart Journal
|
February 4, 2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
Michael Böhm, Robin Young, Pardeep S Jhund, et al.
American Journal of Nephrology
|
December 15, 2017
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial
Finnian R Mc Causland, Brian Claggett, Marc A Pfeffer, et al.
American Journal of Ophthalmology
|
March 3, 2018
Shortest Distance From Fovea to Subfoveal Hemorrhage Border Is Important in Patients With Neovascular Age-related Macular Degeneration
Saleema Kherani, Adrienne W Scott, Adam S Wenick, et al.
Journal of Hepatology
|
June 25, 2017
Human germline hedgehog pathway mutations predispose to fatty liver
Maria J Guillen-Sacoto, Ariel F Martinez, Yu Abe, et al.
Circulation
|
April 30, 2019
High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study
Xiaoming Jia, Wensheng Sun, Ron C Hoogeveen, et al.
European Journal of Heart Failure
|
September 19, 2018
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction
Adriaan A Voors, Sanjiv J Shah, Jeroen J Bax, et al.
Journal of Cardiac Failure
|
May 23, 2023
Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
John W Ostrominski, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure
|
March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Alberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
Nature Medicine
|
March 30, 2026
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial
Scott D Solomon, John J V McMurray, G Michael Felker, et al.
Page
of 188